AQST: חוב לטווח קצר של החברה Aquestive Therapeutics

Aquestive Therapeutics (AQST) leverages the expertise of polymer chemists while recruiting specialized managers to scale sales. The business's prosperity is based on FDA approval and patent protection for mucosal adrenaline delivery systems. The current metric is 0.00. The price action on this chart confirms the stability of the company, which synthesizes films in-house and delegates only primary testing to external partners.

Short-term debt represents the aggregate of all company obligations maturing within one year. This metric accumulates current loans and accrued interest, determining the issuer's liquidity and financial stability. Analyzing the short-term debt structure allows for tracking borrowing trends for working capital. For Aquestive Therapeutics (AQST), such funds are critical for paying external clinical research contractors. Manufacturing outsourcing requires stable funding for current payments.